CO2017009353A2 - Derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd - Google Patents
Derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phdInfo
- Publication number
- CO2017009353A2 CO2017009353A2 CONC2017/0009353A CO2017009353A CO2017009353A2 CO 2017009353 A2 CO2017009353 A2 CO 2017009353A2 CO 2017009353 A CO2017009353 A CO 2017009353A CO 2017009353 A2 CO2017009353 A2 CO 2017009353A2
- Authority
- CO
- Colombia
- Prior art keywords
- activity
- bicyclic heteroaryl
- fused bicyclic
- heteroaryl derivatives
- phd inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención proporciona compuestos de la fórmula (I) y sales farmacéuticamente aceptables de estos, en la que X1, X2, X3, Y1, Y2, R1, R2 y R3 son tal como se define en la memoria descriptiva, procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en terapia.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1504565.1A GB201504565D0 (en) | 2015-03-18 | 2015-03-18 | Novel compounds |
| PCT/JP2016/059782 WO2016148306A1 (en) | 2015-03-18 | 2016-03-17 | Fused bicyclic heteroaryl derivatives having activity as phd inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2017009353A2 true CO2017009353A2 (es) | 2017-11-30 |
Family
ID=53051992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2017/0009353A CO2017009353A2 (es) | 2015-03-18 | 2017-09-14 | Derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US10287286B2 (es) |
| EP (1) | EP3271357B1 (es) |
| JP (1) | JP6726681B2 (es) |
| KR (1) | KR102609431B1 (es) |
| CN (1) | CN107531698B (es) |
| AU (1) | AU2016234209B2 (es) |
| BR (1) | BR112017019653B1 (es) |
| CA (1) | CA2979024C (es) |
| CL (1) | CL2017002354A1 (es) |
| CO (1) | CO2017009353A2 (es) |
| CR (1) | CR20170468A (es) |
| DK (1) | DK3271357T3 (es) |
| DO (1) | DOP2017000209A (es) |
| EA (1) | EA035739B1 (es) |
| EC (1) | ECSP17069696A (es) |
| ES (1) | ES2774052T3 (es) |
| GB (1) | GB201504565D0 (es) |
| GE (2) | GEP20207095B (es) |
| HU (1) | HUE047918T2 (es) |
| IL (1) | IL254277B (es) |
| MX (1) | MX2017011902A (es) |
| MY (1) | MY194873A (es) |
| NZ (1) | NZ735631A (es) |
| PE (1) | PE20180656A1 (es) |
| PH (1) | PH12017501699B1 (es) |
| PT (1) | PT3271357T (es) |
| SG (1) | SG11201707280VA (es) |
| TN (1) | TN2017000384A1 (es) |
| UA (1) | UA123668C2 (es) |
| WO (1) | WO2016148306A1 (es) |
| ZA (1) | ZA201706612B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201806307YA (en) | 2016-02-24 | 2018-09-27 | Pfizer | Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors |
| WO2019034973A1 (en) | 2017-08-14 | 2019-02-21 | Pfizer Inc. | PYRAZOLO [1,5-A] PYRAZIN-4-YL AND RELATED DERIVATIVES |
| EP3808747B1 (en) | 2018-09-13 | 2024-12-18 | Kissei Pharmaceutical Co., Ltd. | Imidazopyridinone compound |
| CN110950806A (zh) * | 2019-11-14 | 2020-04-03 | 安庆博曼生物技术有限公司 | 四乙基氯化铵催化嘧啶环羟基氯代制备方法 |
| JP7504822B2 (ja) * | 2020-03-12 | 2024-06-24 | キッセイ薬品工業株式会社 | イミダゾピリジノン化合物を含む医薬組成物 |
| US11718622B2 (en) | 2020-03-16 | 2023-08-08 | Exelixis Inc. | Heterocyclic adenosine receptor antagonists |
| CN117304171A (zh) * | 2020-04-20 | 2023-12-29 | 深圳市塔吉瑞生物医药有限公司 | 吡嗪取代的烟酰胺的固体形式及其制备和用途 |
| TW202233629A (zh) * | 2020-10-20 | 2022-09-01 | 美商安進公司 | 雜環螺環化合物及使用方法 |
| US12492178B2 (en) | 2021-09-01 | 2025-12-09 | Empathbio, Inc. | Stable polymorph of R-MDMA HCl |
| WO2023072240A1 (en) | 2021-10-28 | 2023-05-04 | Insilico Medicine Ip Limited | Prolyl hydroxylase domain-containing protein (phd) inhibitors and uses thereof |
| CN118715015A (zh) * | 2021-12-17 | 2024-09-27 | 阿克比治疗有限公司 | 选择性phd1抑制剂化合物、组合物和使用方法 |
| EP4457222A4 (en) | 2021-12-28 | 2025-12-24 | Empathbio Inc | MDA AND MDMA NITRIC OXIDE-RELEASING PROMEDICAMENTS |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4209621A (en) | 1979-04-27 | 1980-06-24 | American Cyanamid Company | (Substituted-phenyl)-1,2,4-triazolo[4,3-a]-pyrimidines and (substituted-phenyl)-1,2,4-triazolo[1,5-a]pyrimidines |
| US4572910A (en) * | 1983-03-03 | 1986-02-25 | Riker Laboratories, Inc. | Triazolo[1,5-c]pyrimidines substituted by nitrogen-containing heterocyclic rings |
| DK135184A (da) * | 1983-03-03 | 1984-10-10 | Riker Laboratories Inc | Triazol(4,3-c)- og triazol(1,5-c)pyrimidiner |
| BR0112038A (pt) | 2000-06-30 | 2003-04-01 | Wyeth Corp | Triazolopirimidinas substituìdas como agentes anticâncer |
| JP2010065026A (ja) | 2008-08-13 | 2010-03-25 | Ishihara Sangyo Kaisha Ltd | ピリジル−トリアゾロピリミジン誘導体又はその塩、並びにそれらを含有する有害生物防除剤 |
| JP2010065024A (ja) | 2008-08-14 | 2010-03-25 | Ishihara Sangyo Kaisha Ltd | トリアゾロピリミジン誘導体又はその塩を含有する有害生物防除剤 |
| US8283465B2 (en) * | 2009-07-17 | 2012-10-09 | Japan Tobacco Inc. | Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent |
| JP2011168582A (ja) | 2010-01-21 | 2011-09-01 | Ishihara Sangyo Kaisha Ltd | トリアゾロピリジン誘導体又はその塩、それらの製造方法及びそれらを含有する有害生物防除剤 |
| WO2014030716A1 (ja) * | 2012-08-23 | 2014-02-27 | 田辺三菱製薬株式会社 | ピラゾロピリミジン化合物 |
-
2015
- 2015-03-18 GB GBGB1504565.1A patent/GB201504565D0/en not_active Ceased
-
2016
- 2016-03-17 ES ES16715122T patent/ES2774052T3/es active Active
- 2016-03-17 NZ NZ735631A patent/NZ735631A/en unknown
- 2016-03-17 WO PCT/JP2016/059782 patent/WO2016148306A1/en not_active Ceased
- 2016-03-17 EA EA201792057A patent/EA035739B1/ru unknown
- 2016-03-17 EP EP16715122.4A patent/EP3271357B1/en active Active
- 2016-03-17 DK DK16715122.4T patent/DK3271357T3/da active
- 2016-03-17 UA UAA201708877A patent/UA123668C2/uk unknown
- 2016-03-17 TN TNP/2017/000384A patent/TN2017000384A1/en unknown
- 2016-03-17 GE GEAP201614608A patent/GEP20207095B/en unknown
- 2016-03-17 MY MYPI2017703420A patent/MY194873A/en unknown
- 2016-03-17 US US15/558,824 patent/US10287286B2/en active Active
- 2016-03-17 CN CN201680022416.0A patent/CN107531698B/zh active Active
- 2016-03-17 CA CA2979024A patent/CA2979024C/en active Active
- 2016-03-17 PT PT167151224T patent/PT3271357T/pt unknown
- 2016-03-17 KR KR1020177030091A patent/KR102609431B1/ko active Active
- 2016-03-17 BR BR112017019653-0A patent/BR112017019653B1/pt active IP Right Grant
- 2016-03-17 SG SG11201707280VA patent/SG11201707280VA/en unknown
- 2016-03-17 PH PH1/2017/501699A patent/PH12017501699B1/en unknown
- 2016-03-17 HU HUE16715122A patent/HUE047918T2/hu unknown
- 2016-03-17 JP JP2017549107A patent/JP6726681B2/ja active Active
- 2016-03-17 MX MX2017011902A patent/MX2017011902A/es active IP Right Grant
- 2016-03-17 PE PE2018000126A patent/PE20180656A1/es unknown
- 2016-03-17 GE GEAP201914608A patent/GEAP201914608A/en unknown
- 2016-03-17 AU AU2016234209A patent/AU2016234209B2/en active Active
- 2016-03-17 CR CR20170468A patent/CR20170468A/es unknown
-
2017
- 2017-09-03 IL IL254277A patent/IL254277B/en active IP Right Grant
- 2017-09-14 CO CONC2017/0009353A patent/CO2017009353A2/es unknown
- 2017-09-15 CL CL2017002354A patent/CL2017002354A1/es unknown
- 2017-09-18 DO DO2017000209A patent/DOP2017000209A/es unknown
- 2017-10-02 ZA ZA2017/06612A patent/ZA201706612B/en unknown
- 2017-10-18 EC ECIEPI201769696A patent/ECSP17069696A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017009353A2 (es) | Derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd | |
| MX2018003432A (es) | Compuestos heterociclicos y usos de los mismos. | |
| SV2017005514A (es) | Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos | |
| ECSP16074478A (es) | Compuestos novedosos | |
| MX2020011449A (es) | Oxiesteroles y metodos de uso de los mismos. | |
| ECSP17083003A (es) | Nuevos derivados bicíclicos, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| MX389349B (es) | Derivados de ácido borónico y usos terapéuticos de los mismos. | |
| MX376271B (es) | Compuestos heterocíclicos y usos de los mismos. | |
| NI201400107A (es) | Compuestos de heterociclilo como inhibidores de mek | |
| ECSP17074645A (es) | Azabenzimidazoles y su uso como moduladores del receptor ampa | |
| ECSP15043696A (es) | Compuestos de heteroarilo y sus usos | |
| MX2016014547A (es) | Compuestos para tratar atrofia muscular espinal. | |
| UY35663A (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos | |
| DOP2014000036A (es) | Compuestos de piridazinona y su uso como inhibidores daao | |
| MX2018000280A (es) | Oxiesteroles y metodos de uso de los mismos. | |
| CR20160084A (es) | Derivados de amida como agonistas del receptor del ácido lisofosfatídico | |
| CL2017002498A1 (es) | Piridopirimidinonas y su uso como modulares del receptor nmda | |
| CU20180028A7 (es) | DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, ÚTILES COMO INHIBIDORES DUALES DE DYRK1/CLK1 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN | |
| UY35536A (es) | ?derivados de sulfonamida?. | |
| ECSP16074482A (es) | Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina | |
| ECSP18056196A (es) | Derivados de indano | |
| AR132461A2 (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos | |
| UY35672A (es) | Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos |